To understand the roles of thyroid hormone receptors (TRs) in adipogenesis, we adopted a loss-of-function approach. We generated 3T3-L1 cells stably expressing either TRa1 mutant (TRa1PV) or TRb1 mutant (TRb1PV). TRa1PV and TRb1PV are dominant negative mutations with a frameshift in the C-terminal amino acids. In control cells, the thyroid hormone, tri-iodothyronine (T 3 ), induced a 2 . 5-fold increase in adipogenesis in 3T3-L1 cells, as demonstrated by increased lipid droplets. This increase was mediated by T 3 -induced expression of the peroxisome proliferator-activated receptor g (PPARg) and CCAAT/enhancer-binding protein a (C/EBPa), which are master regulators of adipogenesis at both the mRNA and protein levels. In 3T3-L1 cells stably expressing TRa1PV (L1-a1PV cells) or TRb1PV (L1-b1PV cells), adipogenesis was reduced 94 or 54% respectively, indicative of differential inhibitory activity of mutant TR isoforms. Concordantly, the expression of PPARg and C/EBPa at the mRNA and protein levels was more repressed in L1-a1PV cells than in L1-b1PV cells. In addition, the expression of PPARg downstream target genes involved in fatty acid synthesis -the lipoprotein lipase (Lpl) and
Introduction
Thyroid hormone (tri-iodothyronine, T 3 ) has long been recognized to play a key role in lipid metabolism and thermogenesis. However, the molecular mechanisms by which T 3 regulates lipid homeostasis have not been fully elucidated. The genomic actions of T 3 are mediated by thyroid hormone nuclear receptors (TRs). There are two TR genes, TRa and TRb, located on different chromosomes, to encode three major T 3 binding receptors, a1, b1, and b2 (Cheng 2000) . These TR isoforms, expressed in a tissue-specific and development-regulated manner, regulate growth, differentiation, and development, and maintain metabolic homeostasis. TRs are ligand-dependent transcription factors that bind to specific DNA sequences known as thyroid hormone response elements (TREs) on the promoter of T 3 target genes. The regulation of the transcriptional activity of TRs is complex. In addition to T 3 , their transcriptional activity is further regulated by a host of corepressors and coactivators (Cheng 2000 , O'Malley 2003 .
Recent progress in the understanding of TR action on lipid homeostasis has been achieved via genetically engineered mice. Mice deficient in the Tra gene exhibit a lower body temperature than the wild-type mice, indicating that Tra1 is important in thermogenesis and energy balance (Wikstrom et al. 1998) . Mice lacking the Trb gene have abnormal cholesterol regulation (Gullberg et al. 2002) . Mice devoid of all functional TRs display decreased body temperature and basal metabolic rate, and are cold intolerant due to insufficient heat production (Golozoubova et al. 2004) . These studies revealed that TR isoforms act to regulate different aspects of metabolic homeostasis. More insights into TR actions in lipid metabolism came from the use of loss-of-function approach via knock-in mutations of TR genes in mice. Indeed, knock-in mutant mice harboring different mutations of the Tra gene exhibit abnormalities in lipid metabolism. The Tra1P398H knock-in mutant mice have increased body fat accumulation and elevated serum levels of leptin, glucose, and insulin (Liu et al. 2003) . In contrast, the Tra1R384C knock-in mutant mice exhibit a lean phenotype with a reduction in fat mass (Sjogren et al. 2007) . The Tra1PV mice that harbor a frameshift mutation in the C-terminal 17 amino acids ( Fig. 1 ) display a lean phenotype, partly due to the reduction in the mass of white adipose tissue (WAT; Kaneshige et al. 2001 , Ying et al. 2007 ). The reasons for the different phenotypic manifestations in these three knock-in mutant mice are not clear. The different phenotypes could reflect the differences in the degree of loss of T 3 binding and the potency of dominant negative activity of Tra1 mutants. Tra1PV mice completely lose T 3 binding and exhibit potent dominant negative activity (Kaneshige et al. 2001) . In contrast, Tra1P398H and Tra1R384C mice only partially lose T 3 binding activity (Tinnikov et al. 2002 , Liu et al. 2003 . The weaker dominant negative activity of Tra1R384C is consistent with the restoration of the target gene expression and the rescue of growth retardation in Tra1R384C mice when serum thyroxine concentration was increased tenfold (Tinnikov et al. 2002) .
The expression of Tra1PV mutant in WAT impairs adipogenesis via, in part, the transcriptional repression of the master regulator of adipogenesis, peroxisome proliferation-activated receptor g (Pparg; Ying et al. 2007) . However, despite Trb expression in WAT (Ying et al. 2007) , intriguingly, in the TrbPV mice that harbor the identical PV mutation in the corresponding C-terminal position ( Fig. 1 ; Kaneshige et al. 2000) , no apparent changes in WAT are evident (Araki et al. 2009 ), suggesting mutant TR isoforms mediate distinct impairments in adipogenesis.
To dissect the molecular mechanism underlying the distinct phenotypic manifestation in WAT between Tra1PV and TrbPV mice, we used the 3T3-L1 cell line. This system, developed by Green & Kehinde (1975) in the 1970s, has long been used by investigators as a model cell line to study adipogenesis. To establish the cause-effect relationship, we stably expressed TRa1PV or TRb1PV in 3T3-L1 cells and evaluated the alterations in adipogenesis as compared with parental cells that contained only the vector backbone (control cells). Clones with similar abundance of TRa1PV (denoted as L1-a1PV cells) or TRb1PV (L1-b1PV cells) were used to elucidate the molecular basis of the distinct phenotypic expression in adipogenesis in WAT observed in Tra1PV and TrbPV mice (Araki et al. 2009) . We found that the T 3 -induced adipogenesis was more severely impaired in L1-a1PV cells than in L1-b1PV cells. The expression of two master regulators, PPARg and CCAAT/enhancerbinding protein a (C/EBPa), was found to be more repressed in L1-a1PV cells than in L1-b1PV cells. Consistent with the gene expression patterns, the expression of several key lipogenic enzymes was more severely inhibited by TRa1PV than by TRb1PV. Further analysis indicated that the preferential repression of the C/ebpa gene by TRa1PV was mediated, at least in part, by more avid recruitment of TRa1PV to the promoter complex of the C/ebpa gene. The finding that TR-mediated adipogenesis is isoform dependent raised the possibility that isoform-specific TR ligands could be considered for therapeutic intervention for lipid abnormalities.
Materials and methods
Cell culture 3T3-L1 cells (ATCC #CL-173) were maintained in DMEM with 10% calf serum as described previously (Ying et al. 2007 ).
Generation of 3T3-L1 cell lines stably expressing TRa1PV or TRb1PV by retrovirus transduction
Plasmids
Human TRa1PV and TRb1PV cDNAs were cloned into pFH-IRESneo plasmid ( (Martinez et al. 2001) , a generous gift of R G Roeder, Rockefeller University, New York, NY, USA) to obtain FH-a1PV and FH-b1PV respectively as described previously (Ying et al. 2006) . The pMSCVhygro-FH-a1PV or pMSCVhygro-FH-b1PV vector was prepared by inserting FH-a1PV or FH-b1PV cDNA from pFH-IRESneo-a1PV or pFH-IRESneo-b1PV respectively into pMSCVhygro (Clontech). All plasmids were verified by DNA sequencing.
Retrovirus transduction
EcoPack2-293 ecotropic retrovirus packaging cell lines (Clontech) were cultured in DMEM with 10% fetal bovine serum. Recombinant retroviral transduction of 3T3-L1 cells was performed as described (Ge et al. 2002) . Briefly, EcoPack2-293 cells were seeded at a density of 3!10 6 cells per 10-cm dish. After 24 h, cells were transfected with 22 mg of retrovirus vector by Lipofectamine 2000 reagent (Invitrogen). Forty-eight hours after transfection, the cells were changed into fresh medium. After 12 h, virus-containing supernatant Figure 1 Schematic comparison of the wild-type and mutant TR isoforms. The PV mutation was identified in a patient with resistance to thyroid hormone. It has a C insertion in codon 448 of TRb1 that leads to a frameshift mutation in the C-terminal 14 amino acids. The identical mutation was targeted to the Tra and Trb genes to encode TRb1PV and TRa1PV respectively. The different sequences between the wild-type and mutant TR isoforms at the C-terminal region are indicated.
was collected, filtered through 0 . 45-mm membrane, and supplemented with 8 mg/ml polybrene (Sigma). 3T3-L1 cells were plated at a density of 2!10 5 cells per 10-cm dish 1 day before infection. Cells were incubated with retrovirus for 48 h and split at a density of 2!10 5 cells per 10-cm dish. Cells were selected with 150 mg/ml hygromycin (Invitrogen) for 14 days. The expression of TRa1PV or TRb1PV protein was verified by western blot analysis using anti-FLAG (Sigma-Aldrich), anti-TRb1 C4 (Bhat et al. 1995) , or monoclonal anti-PV antibody (#302; Zhang et al. 2002) .
Induction of adipocyte differentiation
Adipocyte differentiation was induced as described (Ying et al. 2007) . Briefly, after the 3T3-L1 cells reached confluence, they were incubated with DMEM containing 10% resin-stripped calf serum for 48 h. The cells were treated with DMEM containing 10% resin-stripped fetal bovine serum with 1 mM dexamethasone (Sigma) and 0 . 5 mM isobutylmethylxanthine (IBMX) (Sigma) in the presence or absence of 2 nM T 3 for 60 h. Thereafter, cells were subsequently fed every other day with DMEM containing 10% resinstripped fetal bovine serum with or without 2 nM T 3 until being stained with Oil Red O (Sigma) at 7 days after the initiation of stimulation. Quantification of the staining intensities was carried out by drying the stained plates, adding 0 . 8 ml isopropanol per 3 . 5-cm dish, and reading at OD 510 against the control using a stained dish without cells.
Quantitative real-time RT-PCR
RNAs from control 3T3-L1, L1-a1PV, and L1-b1PV cells were extracted using an RNeasy mini kit according to the manufacturer's instructions (Qiagen). DNA was removed by using TURBO DNA-free kit (Ambion, Austin, TX, USA). The determination of mRNA by real-time reverse transcription-PCR (qPCR) was carried out using total RNA (10-50 ng) and primers for Pparg, Lpl, and ap2 as described previously (Ying et al. 2007 , Araki et al. 2009 ). The primer sequences for C/ebpa are forward TTACAACAGGCCAGGTTTCC and backward CTCTGGGATGGATCGATTGT.
Western blot analysis
Cells (control 3T3-L1, L1-a1PV, and L1-b1PV cells) were collected before induction or after induction of adipogenesis. For 100 ml of packed cell volume, 500 ml of lysis buffer (10 mM Tris, pH 7 . 9, 0 . 1 mM EDTA, 10 mM NaCl, 10 mM dithiothreitol, and protease inhibitors) were used to suspend the cells for 15 min on ice. Subsequently, NP40 was added to make a final concentration of 0 . 6% to lyse the cells by gentle vortexing. After centrifugation at 10 000 g for 30 s at 4 8C, the supernatant was removed and the pellet was extracted using an extraction buffer (20 mM HEPES/pH 7 . 9, 0 . 4 M NaCl, and 1 mM EDTA) by vortexing. The suspension was centrigued at 16 000 g for 10 min at 4 8C. In some experiments, the western blot analysis of lysates was done using cells that were harvested by scraping in buffer (1!PBS: 137 mM NaCl, 2 . 7 mM KCl, 10 mM sodium phosphate dibasic, and 2 mM potassium phosphate monobasic, pH 7 . 4) and centrifuged at 2300 g at 4 8C for 4 min, and then the supernatant had been removed. The pelleted cells were incubated in a lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1!Halt phosphatase inhibitor cocktail (Product no.: 78 420, ThermoFisher Scientific, Waltham, MA, USA), and 1! proteinase tablet cocktail inhibitors (Complete Mini EDTA-free; Roche)) for 10 min on ice, vortexed three times, and spun at 16 100 g at 4 8C for 10 min. Supernatant was collected for western blot analysis. The protein concentration of the supernatant was determined by the Bradford method (Pierce Chemical Co., Rockford, IL, USA) with BSA (Pierce Chemical Co.) as the standard. Western blot analysis was carried out as described previously (Ying et al. 2006) . For the detection of PPARg and C/EBPa proteins, nuclear fractions (35 mg) were separated by SDS-PAGE. The primary antibodies used in the western blot analysis were anti-PPARg antibody (1:100 dilution; sc-7273; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-C/EBPa (1:100 dilution; sc-61; Santa Cruz Biotechnology, Inc).
Chromatin immunoprecipitation
Chromatin isolation from control 3T3-L1, L1-a1PV, and L1-b1PV cells was carried out by using a chromatin immunoprecipitation (ChIP) assay kit according to the manufacturer's instructions (Millipore, Billerica, MA, USA). Chromatin solution (1 ml) was immunoprecipitated with the following antibodies: 5 ml of anti-TRb1 antibody (Rockland Immunochemicals, Gilbertsville, PA, USA code: 600-401-A38), anti-TRa1 antibody (1:300 dilution, Rockland Immunochemicals), monoclonal anti-PV antibody (#302; 4 mg (Zhang et al. 2002) ), or IgG (2 mg from kit) for negative control, and anti-AcH3 (2 mg, from ChIP assay's kit) for positive control. The DNA recovered after immunoprecipitation was used as a template for amplification as described previously (Ying et al. 2007) . Two percent of the chromatin solution (20 ml) was used for the input DNA as a control. The primer sequences for the analysis of the TR binding sites for C/ebpa were 5 0 -TAGAGAAGCTGGGCGAAAAGA-3 0 (forward) and 5 0 -CCCACTTCCAGCCAACAGTA-3 0 (reverse). The amplified DNA of 339 bp was analyzed on a 1 . 5% agarose gel with ethidium bromide staining. 
Results

Impairment of adipogenesis in 3T3-L1 cells by TR mutants is isoform dependent
The observation that adipogenesis of WAT is impaired in Tra1PV, but not in TrbPV, mice prompted us to use 3T3-L1 cells to further elucidate the molecular mechanisms underlying the differential effects of TR mutants on adipogenesis. 3T3-L1 cells have long been used by investigators as a model cell line to study adipogenesis. We, therefore, generated 3T3-L1 cells stably expressing TRb1PV (L1-b1PV cells) or TRa1PV (L1-a1PV cells). We chose the clones that stably expressed a similar level of TR mutant isoforms for the study (Fig. 2) . Western blot analysis showed that the abundance of TRa1PV protein in L1-a1PV cells (lane 1, Fig. 2A ) was similar to that of TRb1PV protein in L1-b1PV cells (lane 2, Fig. 2A ). Lane 3 shows that no TR mutant was expressed in the control cells in which only the vector backbone was transfected (denoted as control cells). Figure 2B shows endogenous TRa1 and TRb1 protein abundance in L1-b1PV, L1-a1PV, and control cells detected by western blot analysis. Consistent with that found in white adipocytes of wild-type mice (Ying et al. 2007 ), TRa1 was the major TR isoform detected in these three cell lines. GAPDH was used as loading control in Fig. 2A and B.
To assess whether TRb1PV and TRa1PV differentially affected the adipogenesis in 3T3-L1 cells, we compared T3-enhanced adipogenesis in control cells with that in L1-b1PV and L1-a1PV cells (Fig. 3) . Fig. 3B ). Importantly, Fig. 3B shows that TRa1PV was more potent (94% reduction) than TRb1PV (54% reduction) in the inhibition of the T 3 -induced adipogenesis (compare bar 6 with bar 2 and bar 4 with bar 2; Fig. 3B ). The reduction of T 3 -induced adipogenesis in L1-b1PV and L1-a1PV cells could also be visualized by phase contrast microscopy (Fig. 3C) . The finding that TRa1PV was a stronger inhibitor (compare panel f with panel d, Fig. 3C ) than TRb1PV (compare panel e with panel d, Fig. 3C ) was also apparent by phase contrast microscopy in that fewer lipid-containing cells (cells with dark intense color) were observed in panel f than in panel e (Fig. 3C) . These results are consistent with the findings in vivo that impaired adipogenesis in WAT was detected in Tra1PV mice, but not in TrbPV mice (Ying et al. 2007 , Araki et al. 2009 ).
Repression of key regulators of adipogenesis by TR mutants is isoform dependent
PPARg is also a ligand-dependent transcription factor and a member of the nuclear receptor superfamily. Studies have shown that PPARg is both necessary and sufficient for adipogenesis, and it is therefore known as a 'master regulator' of adipogenesis (Rosen & MacDougald 2006) . To understand the underlying mechanisms by which the two mutant TR isoforms differentially impair adipogenesis in 3T3-L1 cells, we first examined the effect of T 3 on the expression of PPARg at the protein level before and after induction of adipogenesis (Fig. 4A ). Before induction (day 0), very low PPARg protein was observed under experimental conditions in control, L1-b1PV, or L1-aPV cells whether T 3 was present or not (lanes 1, 2, 5, 6, 9, and 10, Fig. 4A ). After induction, both PPARg1 and PPARg2 were induced in control cells (lanes 3 and 4, Fig. 4A ). Importantly, their protein abundance was further increased by T 3 (w2-fold; lane 4). The expression of PPARg1 and PPARg2 proteins, however, was strongly decreased in L1-b1PV (lanes 7-8, Fig. 4A ) and L1-a1PV cells (lanes 11-12, Fig. 4A ). The protein abundance of PPARg1 and PPARg2 in L1-a1PV cells was lower than that in L1-b1PV cells (compare lanes 11-12 with lanes 7-8), indicating that TRa1PV inhibited the expression of PPARg1 and PPARg2 at the protein level more than TRb1PV.
C/EBPa is the founding member of a family of basic region/leucine zipper (bZIP) transcription factors. It is required for the differentiation of 3T3-L1 preadipocytes; inhibition of C/EBPa blocks adipocyte differentiation, whereas overexpression of this C/EBP family member triggers adipocyte differentiation (Darlington et al. 1998 , Obregon 2008 . C/EBPa acts primarily to keep PPARg levels elevated in the cell. Therefore, we also assessed the effect of T 3 on the expression of C/EBPa at the protein level before and after the induction of adipogenesis (Fig. 4B ). Before induction (day 0), the C/EBPa protein level was very low in control, L1-b1PV, or L1-a1PV cells (lanes 1, 2, 5, 6, 9, and 10, Fig. 4B ). After induction, C/EBPa was induced in control cells (lanes 3 and 4, Fig. 4B ). Its protein level was further increased by T 3 (w2-fold, lane 4, Fig. 4B ). In L1-b1PV and L1-a1PV cells, markedly decreased signals were observed (lanes 7-8 and 11-12, Fig. 4B ), indicating that mutations of TRs interfere with the expression of C/EBPa. However, a lower expression of C/EBPa protein was observed in L1-a1PV cells than in L1-b1PV cells (compare lanes 11-12 with lanes 7-8, Fig. 4B ). Panel C shows the corresponding loading control using GAPDH. Taken together, these results demonstrate that T 3 regulates the expression of PPARg and C/EBPa, which are the two master key regulators of adipogenesis.
We further determined the mRNA levels of Pparg and C/ebpa to ascertain whether the expression of these two key regulators is regulated by T 3 and affected by TR mutants at the transcriptional level. Indeed, the expression of Pparg and C/ebpa mRNAs was lower (w25-30% reduction) in the absence of T 3 than in the presence of T 3 (lane 2; Fig. 5A and B respectively). Compared with control, the expression of Pparg mRNA was 45% lower in L1-b1PV cells and 75% lower in L1-a1PV cells (bars 3 and 5 respectively, Fig. 5A ). Consistently, the mRNA level of C/ebpa was 40 and 80% lower in L1-b1PV and L1-a1PV cells respectively compared with the control cells (bars 3 and 5 respectively, Fig. 5B ). It is interesting to note that the expression of these two genes was less repressed at the mRNA levels than at the protein level by TR mutants (see Fig. 4 ). Such discordance could reflect additional post-translational regulation of PPARg and C/EBPa. In L1-b1PV and L1-a1PV cells, T 3 had no significant effect on the extent of PV mutant-mediated repression of Pparg and C/ebpa mRNAs ( Fig. 5A and B respectively) . The functional consequences of the decreased expression of Pparg were evident in that its direct target genes -the lipoprotein lipase (Lpl) and aP2, involved in the lipid synthesis -were concordantly repressed, with a higher extent of repression in L1-a1PV cells than in L1-b1PV cells (compare bars 3 and 5 to bar 1; Fig. 5C and D).
Differential occupancy of mutant TR isoforms on the C/ebpa gene promoter
To further understand how TR mutant isoforms differentially impaired adipogenesis, we focused on the study of the C/ebpa gene, an essential transcription factor in the induction of adipogenesis in 3T3-L1 cells (Darlington et al. 1998 , Obregon 2008 ). The C/ebpa gene is a direct TR target gene with several TREs identified in the promoter of the C/ebpa gene (Menendez-Hurtado et al. 2000) . The finding that TR mutant isoforms differentially repressed the expression of C/ebpa (Fig. 5A ) prompted us to test the hypothesis that differential recruitment of mutant isoforms to the promoter could underlie differential impairment of adipogenesis by TR mutant isoforms. We, therefore, used ChIP to address this question (Fig. 6) . In control cells, when antibodies recognizing specific TR isoforms were used, TRa1 and TRb1 were found to be recruited to TREs on the promoter of the C/ebpa gene (lanes 5 and 6, Fig. 6 ). When the monoclonal antibody recognizing specifically the PV mutated sequences (#302) was used, only background noise (lane 7) similar to that observed in negative controls (lane 2, no antibody; lane 3, an irrelevant IgG) was seen.
In contrast, in L1-b1PV cells, a strong signal was detected when anti-PV antibody was used, indicating the recruitment of b1PV to the TREs on the promoter of the C/ebpa gene (lane 14 (nZ6). *P!0 . 05 and **P!0 . 01. Figure 4 Abundance of PPARg and C/EBPa proteins in 3T3-L1, L1-b1PV, and L1-a1PV cells. Western blot analysis was carried out using nuclear extracts from control 3T3-L1, L1-b1PV, and L1-a1PV cells before induction of adipogenesis (day 0: lanes 1, 2, 5, 6, 9, and 10) and after induction of adipogenesis (day 7: lanes 3, 4, 7, 8, 11, and 12) in the absence (lanes 1, 3, 5, 7, 9, and 11) or presence of T 3 (2 nM; lanes 2, 4, 6, 8, 10, and 12) . Western blot analysis was performed using the antibodies against PPARg1/ PPARg2 (A), C/EBPa (B), and GAPDH (C). GAPDH was used as a loading control. recruitment of TRa1PV to the promoter of the C/ebpa gene. These results suggest that a higher occupancy by TRa1PV than by TRb1PV on the promoter of the C/ebpa gene, which, in part, could underlie a more severe impairment of adipogenesis by TRa1 mutations.
Discussion
It has long been known that T 3 plays a critical role in lipid metabolism by regulating genes involved in lipogenesis and lipolysis. The underlying mechanisms, however, have only begun to be unraveled in recent years. Genetically engineered mice are valuable tools to gain insights into the role of TRs in lipid metabolism and energy balance. Mice deficient in Tra1 exhibit lower body temperature (Wikstrom et al. 1998) , indicative of the importance of Tra1 in thermogenesis. Mice deficient in Trb display abnormalities in cholesterol metabolism (Gullberg et al. 2002) , demonstrating that Trb plays a major role in cholesterol homeostasis. Significant advances in the understanding of the roles of Tra1 in adipogenesis came from the mice with knock-in mutations in the Tra gene. Mice that are heterozygous for a Tra1P398H mutation are obese with increased visceral adiposity and hepatic steatosis (Liu et al. 2003) . In adipose tissue, the norepinephrinemediated lipolysis in WAT is blocked, and hormonesensitive lipase in adipose tissue is decreased. In contrast to the Tra1P398H mutant mice, mice with a Tra1R384C mutation are lean and hypermetabolic with reduction in fat depots (Sjogren et al. 2007 ). Similar to the lean phenotype exhibited by Tra1R384C mutant mice, Tra1PV mice are dwarfs with reduced WAT mass across a variety of depots (Ying et al. 2007 ). TRa1PV acts to transcriptionally repress the expression of the Pparg gene, resulting in impaired adipogenesis. Intriguingly, while Trb is expressed in WAT (Ying et al. 2007) , no apparent reduction in WAT mass was evident in TrbPV mice (Araki et al. 2009 ), indicating distinct phenotypic expression in the adipogenesis in WAT between these two mutant mice. In the present study, the creation of stable 3T3-L1 cell lines expressing a similar level of TRa1PV or TRb1PV proteins allowed the dissecting of the differential role of TR isoforms in adipogenesis. Indeed, TRa1PV was a stronger repressor than TRb1PV in blocking T 3 -mediated adipogenesis in 3T3-L1 cells by inhibiting the expression of two master regulators, PPARg and C/EBPa. The stronger repression by TRa1PV was due, in part, to a stronger recruitment of TRa1PV than of TRb1PV to the promoter of the C/ebpa gene (Fig. 6) . As a result, the expression of the C/ebpa gene was repressed, leading to more impaired adipogenesis in L1-a1PV cells than in L1-b1PV cells (Fig. 3) . Thus, the present study has provided direct evidence to link the mutations of the TRa gene to the impaired adipogenesis in WAT. Currently, it is not clear how TRa1PV was preferentially recruited to the promoter complex of the C/ebpa gene. TRa1PV and TRb1PV differ mainly in the aminoterminal A/B domain (see Fig. 1 ). Thus, it is reasonable to speculate that the amino-terminal A/B domain of TRa1PV could affect the folding of the tertiary structure such that TRa1PV could bind to TREs stronger than TRb1PV on the promoter of the C/ebpa gene. Alternatively, the amino-terminal A/B domain could facilitate the formation of a favorable conformation for TRa1PV to interact more favorably with other coregulators (e.g. corepressors) to stabilize the TRa1PV-DNA complex on the C/ebpa gene promoter. These two possibilities are not mutually exclusive and could, in fact, act in concordance to strengthen the interaction of TRa1PV with the promoter to block the expression of the C/ebpa gene, thereby impairing adipogenesis in 3T3-L1 cells. Figure 6 Differential recruitment of TRb1PV and TRa1PV to the promoter of the C/ebpa gene as determined by ChIP analysis. ChIP assays were performed using control 3T3-L1 (lanes 1-7) , L1-b1PV (lanes 8-14) , and L1-a1PV (lanes 15-21) cells after T 3 -induced adipogenesis on day 9. Antibodies used in the chromatin immunoprecipitation were anti-Ac-H3 antibody as a positive control (lanes 4, 11, and 18), anti-TRa1 antibody (lanes 5, 12, and 19), anti-TRb1 antibody (lanes 6, 13, and 20), and anti-PV antibody (lanes 7, 14, and 21). The negative controls were no antibody (lanes 2, 9, and 16) as well as an irrelevant IgG (lanes 3, 10, and 17). The chromatin immunoprecipitated and recovered DNA was used as a template for PCR amplification of the receptor-binding region in the promoter of the C/ebpa gene. Two percent of the chromatin solution (20 ml) was used for input DNA as a control. Three separate experiments were performed, and the representative results are shown. The finding that TRa1PV had a more deleterious effect than TRb1PV on the adipogenesis in 3T3-L1 cells provided new insights to understand the observation that WAT mass is reduced in Tra1PV mice, but not in TrbPV mice compared with the wild-type mice (Araki et al. 2009 ). Tra1 is a major TR isoform in WAT; therefore, mutation of a major TR isoform (i.e. Tra1) results in the loss of function critical for adipogenesis. In TrbPV mice, mutation of a minor TR isoform (i.e. TRb1) cannot completely block the effect of TRa1, the major TR in WAT. Furthermore, TRb1PV, as shown in the present study, was not as strong as TRa1 in interacting with TRE on the promoter of the C/ebpa gene promoter, thereby making TRb1PV less effective in blocking adipogenesis in WAT in TrbPV mice. However, besides the preferential interaction of TRa1PV with the promoter of the C/ebpa gene, other mechanisms, yet to be uncovered, could also contribute to the more severe impairment in adipogenesis by TRa1PV.
As obesity and atherosclerosis have become major health concerns in Western countries, there is an increasing need to develop novel treatment strategies. Thyroid hormone mimetics that have specificity toward TRa1 or TRb1 are being developed to derive benefits in treating metabolic diseases but without undesirable effects on other target organs (Baxter & Webb 2009 ). The finding that TRa1PV was more effective than TRb1PV in blocking adipogenesis suggests that TRa1 could be considered as a potential therapeutic target for decreasing adipose tissue and reducing serum fatty acids. Moreover, 3T3-L1 cells stably expressing TRa1PV or TRb1PV could be used as model cell lines to further elucidate the role of T 3 via TR in adipogenesis.
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